Evidence map›Paper›PMID 4356847›Full record

Trial reportJAMA1973

The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group.

Registry-linked trialAbstract readClinical TrialControlled Clinical Trial
PubMed
In one paragraph

Trial report in JAMA, 1973. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000482. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000482 phase3completed

Coronary Drug Project

Ran1965Registered outcomes0Posted comparisons0ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial InfarctionArmsclofibrate clofibrate, dextrothyroxine sodium, Estrogen, niacin
Open the trial in the graph
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Coronary drug project: experience with niacin. Coronary Drug Project Research Group.European journal of clinical pharmacology · 1991 · on this map
    Trial
  7. Sex, hormones, and lung health.Physiological reviews · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug EvaluationAdultAnticholesteremic AgentsClinical Trials as TopicClofibrateCoronary DiseaseDextrothyroxineDrug Therapy, CombinationEstrogens, Conjugated (USP)Follow-Up StudiesHumansLipoproteins, LDLLipoproteins, VLDLMaleMiddle AgedMyocardial InfarctionAnticholesteremic AgentsClofibrateDextrothyroxineEstrogens, Conjugated (USP)Lipoproteins, LDLLipoproteins, VLDLNicotinic AcidsPlacebosSodium

Identifiers

PMID4356847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.